Hybridon, Inc. – Trademark Portfolio
Entity Type: 03
Hybridon, Inc. holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include IMO and IDERA. The owner is based in MILFORD, MA.
345 VASSAR STREET
MILFORD, MA 02139
Showing of trademarks Trademarks
Trademark Classifications
Hybridon, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Hybridon, Inc. have?
Hybridon, Inc. has 23 U.S. trademarks filed with the USPTO. Of these, 3 registered, 15 abandoned, 5 cancelled.
What trademark classes does Hybridon, Inc. file in?
Hybridon, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Hybridon, Inc.'s most well-known trademarks?
Hybridon, Inc.'s registered trademark portfolio includes well-known marks such as IMO and IDERA. These are among 3 currently registered trademarks in the portfolio.
What is Hybridon, Inc.'s trademark registration success rate?
Hybridon, Inc. has a 13% trademark registration rate, with 3 out of 23 resolved applications resulting in successful registration. Currently, 0 applications are pending review.